$29.25 Million in Sales Expected for REGENXBIO Inc. (NASDAQ:RGNX) This Quarter

Brokerages expect REGENXBIO Inc. (NASDAQ:RGNXGet Rating) to report $29.25 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for REGENXBIO’s earnings, with the lowest sales estimate coming in at $22.04 million and the highest estimate coming in at $38.20 million. REGENXBIO posted sales of $22.04 million in the same quarter last year, which would suggest a positive year over year growth rate of 32.7%. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that REGENXBIO will report full year sales of $215.26 million for the current year, with estimates ranging from $102.47 million to $415.20 million. For the next year, analysts expect that the company will post sales of $193.62 million, with estimates ranging from $102.47 million to $321.07 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for REGENXBIO.

REGENXBIO (NASDAQ:RGNXGet Rating) last released its quarterly earnings data on Tuesday, March 1st. The biotechnology company reported $6.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.28 by $2.39. REGENXBIO had a net margin of 27.18% and a return on equity of 22.35%. The company had revenue of $398.66 million for the quarter, compared to analysts’ expectations of $255.76 million. During the same quarter in the prior year, the firm earned ($1.24) EPS. The business’s revenue was up 1759.0% on a year-over-year basis.

A number of equities research analysts recently weighed in on RGNX shares. SVB Leerink lowered their target price on shares of REGENXBIO from $29.00 to $25.00 and set a “market perform” rating on the stock in a report on Wednesday, March 2nd. StockNews.com started coverage on shares of REGENXBIO in a report on Thursday, March 31st. They issued a “hold” rating on the stock. TheStreet upgraded shares of REGENXBIO from a “d” rating to a “c” rating in a report on Tuesday, March 1st. Morgan Stanley increased their price objective on shares of REGENXBIO from $50.00 to $51.00 and gave the company an “overweight” rating in a research note on Wednesday, March 23rd. Finally, Chardan Capital reiterated a “buy” rating on shares of REGENXBIO in a research note on Monday, April 11th. Four equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $45.88.

Large investors have recently bought and sold shares of the stock. Hennion & Walsh Asset Management Inc. raised its holdings in shares of REGENXBIO by 52.1% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 30,888 shares of the biotechnology company’s stock worth $1,295,000 after purchasing an additional 10,576 shares during the period. New York State Teachers Retirement System raised its holdings in shares of REGENXBIO by 0.9% in the 4th quarter. New York State Teachers Retirement System now owns 45,631 shares of the biotechnology company’s stock worth $1,492,000 after purchasing an additional 400 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of REGENXBIO by 101.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 277,700 shares of the biotechnology company’s stock worth $9,081,000 after purchasing an additional 139,947 shares during the period. Comerica Bank grew its stake in REGENXBIO by 3.4% in the 3rd quarter. Comerica Bank now owns 32,298 shares of the biotechnology company’s stock valued at $1,167,000 after buying an additional 1,072 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in REGENXBIO by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 665,419 shares of the biotechnology company’s stock valued at $27,894,000 after buying an additional 2,711 shares in the last quarter. 87.57% of the stock is currently owned by institutional investors.

RGNX opened at $22.23 on Friday. REGENXBIO has a fifty-two week low of $22.03 and a fifty-two week high of $46.46. The firm has a market capitalization of $955.58 million, a PE ratio of 10.34 and a beta of 1.12. The company’s 50-day moving average is $29.75 and its 200 day moving average is $30.44.

About REGENXBIO (Get Rating)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Further Reading

Get a free copy of the Zacks research report on REGENXBIO (RGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.